Full Title
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE (A032201) (CIRB)Purpose
Researchers want to see how well tivozanib plus pembrolizumab works in people with kidney cancer. The people in this study had surgery for renal cell carcinoma and have a high risk of it coming back.
Tivozanib blocks the action of an abnormal protein that tells tumor cells to multiply. This helps stop tumor cell spread. It is taken orally (by mouth).
Pembrolizumab works by helping the immune system attack cancer and inhibiting the growth and spread of tumor cells. It is given intravenously (by vein).
Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone to treat renal cell cancer. If you take part in this study, you will be randomly assigned to get pembrolizumab alone or with tivozanib.
Who Can Join
To join this study, there are a few conditions. You must:
- Have no evidence of cancer after surgery for clear cell renal cell carcinoma. The surgery must have happened at least 4 weeks but no more than 16 weeks before getting the study treatment.
- Have a high risk of kidney cancer coming back.
- Not have had prior anti-cancer medications for kidney cancer.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Darren Feldman’s office at 646-888-4740.